AGN - NGM Biopharmaceuticals And NASH: Making Progress
Any man or institution that tries to rob me of my dignity will lose - Nelson Mandela
Introduction
The once dormant clinical research and development of therapies for the non-viral liver disease, NASH, is now characterized by intense competition with over 30 innovative drug candidates currently in clinical development. This is a brief introductory article on privately held NGM Biopharmaceuticals Inc. (NGM) which has a $75M pending IPO. The west coast (San Francisco, California) based clinical-stage biopharma focuses on the clinical development of innovative therapies for cardiometabolic disorders of high unmet medical